Loading clinical trials...
Loading clinical trials...
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospecti...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fudan University
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more
NCT07144826 · Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, and more
NCT07023627 · Ovarian Cancer
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Shanghai, Shanghai Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions